T1	condition 14 33	cardiac dysfunction
T2	intervention 449 460	candesartan
T3	intervention 468 488	Î²-blocker metoprolol
T4	No-of-participants 750 753	130
T5	eligibility 754 818	adult women with early breast cancer and no serious co-morbidity
T6	control 926 934	placebos
T7	outcome-Measure 1013 1027	change in LVEF
T8	outcome 1156 1216	no interaction between candesartan and metoprolol treatments
T9	outcome 1234 1257	overall decline in LVEF
